vedomostiregmedРегуляторные исследования и экспертиза лекарственных средствRegulatory Research and Medicine Evaluation3034-30623034-3453Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)vedomostiregmed-43Research ArticleФАРМАКОЭКОНОМИКАPHARMACOECONOMICSАнализ структуры затрат на фармакотерапию инфаркта мозга в стационаре в 2009-2011 ггAnalysis of the cost of pharmacotherapy of ischemic stroke in hospital in 2009-2011МихееваН. В.MikheevaN. V.noemail@neicon.ruРешетькоО. В.ReshetkoO. V.reshetko@yandex.ruКурносовС. И.KurnosovS. I.noemail@neicon.ruГБОУ ВПО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава РоссииРоссияState Budgetary Educational Institution HVE «Saratov State Medical University named after V.I. Razumovsky» of the Ministry of Health of the Russian FederationRussian FederationГУЗ «Областная клиническая больница»РоссияState Healthcare Institution «Regional Clinical Hospital»Russian Federation201513022018025964Copyright © Михеева Н.В., Решетько О.В., Курносов С.И., 20182018Михеева Н.В., Решетько О.В., Курносов С.И.Mikheeva N.V., Reshetko O.V., Kurnosov S.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vedomostincesmp.ru/jour/article/view/43

Фармакоэкономический анализ включал оценку структуры прямых затрат на фармакотерапию инфаркта мозга в 2009-2011 годах в стационарных лечебных учреждениях г. Саратова (762 пациента) с использованием АВС- и частотного анализа. По результатам этого анализа было выявлено наличие в группе «А» лекарственных препаратов без доказанной эффективности и очень высокая доля затрат на них (75,67%) от бюджета закупок. Отмечено недостаточное применение лекарственных средств, применяемых при лечении инфаркта мозга и имеющих научно обоснованные доказательства эффективности и безопасности. Напротив, широкое распространение получило применение препаратов без доказанной эффективности, что приводит к увеличению финансовых потерь государства и населения. Результаты проведенного клинико-экономического анализа показали необходимость изменения структуры затрат на фармакотерапию данного заболевания в стационарах города.

Pharmacoeconomic analysis includes the assessment of direct cost structure in pharmacotherapy of cerebral infarction for the period of 2009-2011 in healthcare institutions in Saratov (762 patients) based on ABC analysis and frequency analysis. The results of the mentioned analysis showed the presence of drugs without proven efficacy and a very high associated cost component (75.67%) of purchasing budget in drug group «A». It was revealed, that the drugs of scientifically substantiated efficacy and safety are not used sufficiently in treatment of cerebral infarction. On the other hand the drugs without proven efficacy are widely used, which leads to an increase in financial losses of the state and population. The results of clinical and economic analysis showed the need for changing the cost structure for drug therapy of the mentioned disease in hospitals.

ABC-analysisfrequency analysispharmacoeconomicscerebral infarctionАВС-анализчастотный анализфармакоэкономикаинфаркт мозгаReferencesHojs R. Renal Dysfunction and Ischemic Stroke. Scientific Journal of the Faculty of Medicine in Nis. 2013; 30(4): 185-191.Hojs R. Renal Dysfunction and Ischemic Stroke. Scientific Journal of the Faculty of Medicine in Niš. 2013; 30(4): 185–191.Белоусов Д.Ю. Фармакоэкономика: зачем, где и как проводить фармакоэ-кономические исследования? Фармакоэкономика 2011; (1): 13-15.Belousov DY. Pharmacoeconomics: why, where and how to conduct pharmacoeconomic studies? Farmakoekonomika 2011; (1): 13–15 (in Russian).Островская В.О. Оценка реальной клинической практики: лечение пациентов с острым нарушением мозгового кровообращения. Лекарственный вестник 2012; 6(46): 31-38.Ostrovskaya VO. Evaluation of clinical practice: the treatment of patients with acute stroke. Lekarstvenny vestnik 2012; 6(46): 31–38 (in Russian).Фонякин А.В. Актуальные направления вторичной профилактики ишемического инсульта. Нервные болезни 2012; (2): 2-7.Fonyakin AV. Topical areas of secondary prevention of ischemic stroke. Nervnye bolezni 2012; (2): 2–7 (in Russian).Шандалин В.А. Вторичная профилактика ишемического инсульта: от рекомендаций - к реальной клинической практике. Неврология, нейропсихиатрия, психосоматика 2012; (2): 35-41.Shandalin VA. Secondary prevention of ischemic stroke: from recommendations – to the clinical practice. Nevrologiya, neyropsihiatriya, psihosomatika 2012; (2): 35–41.Laslett L.J. The Worldwide Environment of Cardiovascular Disease: Prevalence, Diagnosis, Therapy, and Policy Issues. A Report From the American College of Cardiology. J Am Coll Cardial. 2012; 60(25): 1-49.Laslett LJ. The Worldwide Environment of Cardiovascular Disease: Prevalence, Diagnosis, Therapy, and Policy Issues. A Report From the American College of Cardiology. J Am Coll Cardial. 2012; 60(25): 1–49.Алфимова Г.Ю. Регистр инсульта в Смоленской области. Бюллетень сибирской медицины 2008; (5): 19-23.Alfimova GYu. Register stroke in the Smolensk region. Bulleten sibirskoy meditsiny 2008; (5): 19–23 (in Russian).Мартынчик С.А. Медико-экономическая оценка и обоснование совершенствования организационных форм оказания стационарной помощи при мозговом инсульте. Available from: http://vestnik.mednet.ru/content/view/473/30/lang.ru/.Martynchik SA. Medico-economic evaluation and justification of improving organizational forms of inpatient care for stroke. Available from: http://vestnik.mednet.ru/content/view/473/30/lang.ru/ (in Russian).Симерзин В.В. Рациональная фармакотерапия в кардиологии. Вестник Самарского государственного университета - Естественнонаучная серия 2008; 2(61): 303-11.Simerzin VV. Rational Pharmacotherapy in Cardiology. Vestnik Samarskogo gosudarstvennogo universiteta 2008; 2(61): 303–11.Wiffen P. Adverse drug reactions in hospital patients: a systematic review of the prospective and retrospective studies. Bandolier Extra 2002; June: 1-16.Wiffen P. Adverse drug reactions in hospital patients: a systematic review of the prospective and retrospective studies. Bandolier Extra 2002; June: 1–16.Сапожникова И.Е. Лечение сердечно-сосудистых заболеваний у пациентов с сахарным диабетом 2-го типа в реальной клинической практике. Рациональная фармакотерапия в кардиологии 2009; (3): 8-13.Sapozhnikova IE. Treatment of cardiovascular diseases in patients with Type 2 diabetes in the clinical practice. Ratsionalnaya farmakoterapiya v kardiologii 2009; (3): 8–13 (in Russian).Котельников Г.П. Доказательная медицина. Научно-обоснованная медицинская практика: Монография. Самара: СамГМУ; 2000.Kotelnikov GP. Evidence-based medicine. Evidence-based medical practice: Monograph. Samara: Samara State Medical University; 2000 (in Russian).World Health Organisation: The World Medicines Situation 2011. Rational use of medicines. Geneva: WHO; 2011.World Health Organisation: The World Medicines Situation 2011. Rational use of medicines. Geneva: WHO; 2011.Стародубов В.И. Концептуальные вопросы развития здравоохранения и фармацевтического сектора Российской Федерации. СПб: Издательство СПб ГМУ; 1999.Starodubov VI. Conceptual issues of health care and pharmaceutical sector of the Russian Federation. St. Petersburg: St. Petersburg State Medical University; 1999. (in Russian).Белоусов Ю.Б. Основы клинической фармакологии и рациональной фармакотерапии. Том I. Руководство для практикующих врачей. М.: Бионика; 2002.Belousov YuB. Fundamentals of clinical pharmacology and rational pharmacotherapy. Volume I. Guidelines for practitioners. Moscow: Bionika; 2002 (in Russian).Петров В.И. Клиническая фармакология и фармакотерапия в реальной врачебной практике: мастер-класс. М.: ГЭОТАР-Медиа; 2011.Petrov VI. Clinical pharmacology and pharmacotherapy in real medical practice: a master class: the textbook. Moscow: GEOTAR-Media; 2011 (in Russian).Белоусов Д.Ю. Фармакоэкономика: зачем, где и как проводить фармакоэ-кономические исследования? Фармакоэкономика 2011; (1): 13-15.Belousov DYu. Pharmacoeconomics: why, where and how to conduct pharmacoeconomic studies? Farmakoekonomika 2011; (1): 13–15 (in Russian).Ягудина Р.И. Методология анализа «затраты-эффективность» при проведении фармакоэкономических исследований. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология 2012; 5(4): 3-8.Yagudina RI. Analysis Methodology «cost-effectiveness» in conducting pharmacoeconomic studies. Farmakoekonomika 2012; 5(4): 3–8 (in Russian).Гусев Е.И. Неврология. Национальное руководство. М.: ГЭОТАР-Медиа; 2009.Gusev EI. Neurology. National guide. Moscow: GEOTAR-Media; 2009 (in Russian).Saver J.L. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis. 2008; 5(4): 167-77.Saver JL. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis. 2008; 5(4): 167–77.Bolland K. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. Pharm Stat. 2009; 8(2): 136-49.Bolland K. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. Pharm Stat. 2009; 8(2): 136–49.Davalos A. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012; 380(9839): 349-57.Dávalos A. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012; 380(9839): 349–57.Álvarez-Sabín J. The Role of Citicoline in Neuroprotection and Neurorepair in Ischemic Stroke. Brain Sci. 2013; 3(3): 1395-414.Álvarez-Sabín J. The Role of Citicoline in Neuroprotection and Neurorepair in Ischemic Stroke. Brain Sci. 2013; 3(3): 1395–414.Overgaard К. The Effects of Citicoline on Acute Ischemic Stroke: A Review. The Journal of Stroke & Cerebrovascular Diseases 2014; 23(7): 1764-69.Overgaard К. The Effects of Citicoline on Acute Ischemic Stroke: A Review. The Journal of Stroke & Cerebrovascular Diseases 2014; 23(7): 1764–69.European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines formanagement of ischaemic strokea nd transient ischaemic attack. Cerebrovasc Dis. 2008; 2 5: 457-507.European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines formanagement of ischaemic strokea nd transient ischaemic attack. Cerebrovasc Dis. 2008; 25: 457–507.Jauch E.C. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 31 (4): 870-947.Jauch EC. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 31(4): 870–947.Kamphuisen P.W. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost. 2005; (3): 1187-94.Kamphuisen PW. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost. 2005; (3): 1187–94.Diener H.C. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: Results of the protect trial. Stroke 2006; 37: 139-44.Diener HC. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: Results of the protect trial. Stroke 2006; 37: 139–44.Sherman D.G. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (prevail study): An open-label randomised comparison. Lancet 2007; 369: 1347-55.Sherman DG. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (prevail study): An open-label randomised comparison. Lancet 2007; 369: 1347–55.Bardutzky J. Antiedema Therapyin Ischemic Stroke. Stroke 2007; 38: 3084-94.Bardutzky J. Antiedema Therapyin Ischemic Stroke. Stroke 2007; 38: 3084–94.Bath P.M. Theophylline, aminophylline, caffeine and analogues for acute ischaemic stroke (Review). The Cochrane Collaboration 2009; (1): 1-14.Bath PM. Theophylline, aminophylline, caffeine and analogues for acute ischaemic stroke (Review). The Cochrane Collaboration 2009; (1): 1–14.Norris J.W. High dose steroid treatment in cerebral infarction. Br Med J (Clin Res Ed) 1986; 292(6512): 21-23.Norris JW. High dose steroid treatment in cerebral infarction. Br Med J (Clin Res Ed) 1986; 292(6512): 21–23.Qizilbash N. Corticosteroids for acute ischaemic stroke. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12076379Qizilbash N. Corticosteroids for acute ischaemic stroke. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12076379Sandercock P.A. Corticosteroids for acute ischaemic stroke. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21901674Sandercock PA. Corticosteroids for acute ischaemic stroke. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21901674Adams H.P. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association. American Stroke Association. Stroke 2007; 38: 1655-711.Adams HP. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association. American Stroke Association. Stroke 2007; 38: 1655–711.Зиганшина Л.Е. Церебролизин в лечении острого ишемического инсульта. Вестник РАМН 2013; (1): 21-29.Ziganshina LE. Cerebrolysin in the treatment of acute ischemic stroke. Vestnik RAMN 2013; (1): 21–29 (in Russian).PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 1995; 108(9): 710-17.PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 1995; 108(9): 710–17.PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.PROGRESS Collaborative Group. Randomised trial of perindopril-based blood- pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.Castillo J. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain in jury and poor stroke out come. Stroke 2004; 35: 520-26.Castillo J. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain in jury and poor stroke out come. Stroke 2004; 35: 520–26.Eveson D.J. Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow-up. Am J Hypertens 2007; 20(3): 270-7.Eveson DJ. Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow-up. Am J Hypertens 2007; 20(3): 270–7.Amarenco P. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355: 549-59.Amarenco P. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355: 549–59.Furie K.L. Heart Protection Study Collaborative Group: Mrc/bhf heart protection study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.Furie KL. Heart Protection Study Collaborative Group: Mrc/bhf heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7–22.

The authors declare that there are no conflicts of interest present.